New class of antibody cancer drug shows promise
Drug Discovery World
JULY 26, 2023
Results from the trial, published in Nature Communications , found that MOv18 IgE was well-tolerated in the majority of patients and was able to shrink the tumour of a patient with ovarian cancer who had not responded to conventional therapy.
Let's personalize your content